Last reviewed · How we verify
Avibactam (AVI)
Avibactam is a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation by binding to and inactivating bacterial beta-lactamases.
Avibactam is a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation by binding to and inactivating bacterial beta-lactamases. Used for Complicated urinary tract infections (cUTI) in combination with ceftazidime, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in combination with ceftazidime, Complicated intra-abdominal infections (cIAI) in combination with ceftazidime.
At a glance
| Generic name | Avibactam (AVI) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Beta-lactamase inhibitor |
| Target | Serine beta-lactamases and metallo-beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Avibactam is a non-beta-lactam beta-lactamase inhibitor that works through a mechanism distinct from traditional inhibitors. It binds covalently to serine beta-lactamases and reversibly to metallo-beta-lactamases, preventing these enzymes from breaking down beta-lactam antibiotics. This allows beta-lactam drugs to remain active against otherwise resistant bacteria, restoring their therapeutic efficacy.
Approved indications
- Complicated urinary tract infections (cUTI) in combination with ceftazidime
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in combination with ceftazidime
- Complicated intra-abdominal infections (cIAI) in combination with ceftazidime
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
Key clinical trials
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
- Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
- A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) (PHASE2)
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Real-World Study of Ceftazidime Avibactam in China
- Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avibactam (AVI) CI brief — competitive landscape report
- Avibactam (AVI) updates RSS · CI watch RSS
- Pfizer portfolio CI